Skip to main
RXST

RxSight (RXST) Stock Forecast & Price Target

RxSight (RXST) Analyst Ratings

Based on 9 analyst ratings
Hold
Strong Buy 11%
Buy 0%
Hold 67%
Sell 22%
Strong Sell 0%

Bulls say

RxSight is well positioned for long-term success due to its unique customizable intraocular lens technology, growing adoption rates, and strong financial performance with a gross margin well above consensus and operating expenses down compared to the previous year. However, risks to consider include potential challenges in commercial execution, competition in the market, and the need for additional financing. Upside drivers could include faster than expected growth in installed base and higher utilization. Overall, the company has promising potential and a solid foundation for future growth.

Bears say

RxSight is currently facing significant headwinds due to slower revenue growth and lower LDD placements, leading to cash burn. The company's 2026 guidance falls short of analysts' expectations, and their lower unit growth in LALs and LDDs is concerning. Additionally, their revenue mix and GM may be negatively impacted by higher-priced inventory and lower LDD sales in 2H26. Their progress OUS is promising, but may not generate meaningful revenue in the near term.

RxSight (RXST) has been analyzed by 9 analysts, with a consensus rating of Hold. 11% of analysts recommend a Strong Buy, 0% recommend Buy, 67% suggest Holding, 22% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of RxSight and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About RxSight (RXST) Forecast

Analysts have given RxSight (RXST) a Hold based on their latest research and market trends.

According to 9 analysts, RxSight (RXST) has a Hold consensus rating as of May 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.78, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.78, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

RxSight (RXST)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.